Clinical Trial: Golidocitinib in Patients With Mycosis Fungoides/Sezary Syndrome and T-Cell Large Granular Lymphocytic Leukemia

U.S., July 7 -- ClinicalTrials.gov registry received information related to the study (NCT07682792) titled 'Golidocitinib in Patients With Mycosis Fungoides/Sezary Syndrome and T-Cell Large Granular Lymphocytic Leukemia' on June 26.

Brief Summary: This is an open-label, single-institution pilot study of single-agent golidocitinib enrolling up to 24 patients in two cohorts: a) advanced-stage mycosis fungoides/Sezary syndrome (MF/SS), n=12, or b) T-cell large granular lymphocytic leukemia (T-LGLL) requiring treatment, n=12. Patients will receive single agent golidocitinib at the previously established dose of 150 mg QD as determined in the phase I and II studies of golidocitinib.

Study Start Date: Sept. 30

Study Type: INTERVENTIONAL

Condi...